Developments of Phase 3 Trial: BOSTON Bortezomib in combination with Selinexor for treating Myeloma

Michael Kauffman, MD and CEO from Karyopharm Therapeutics Inc discusses developments of Phase 3 trial: BOSTON - Bortezomib in combination with Selinexor for treating myeloma at the 2017 American Socie... Author: ASHReport Added: 01/22/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts